Despite this simplicity, our integrated approach provided multiple testable hypotheses for the complex KRAS NSCLC cell signaling network, proposed possible drug resistance mechanisms, and suggested better treatment strategies. This evidence concerns the gene KRAS and non-small cell lung carcinoma.